Table 1.
Baseline Demographics and Clinical Characteristics in the Intention-to-Treat–Exposed Population
| Demographic/Characteristic | Dolutegravir/ Lamivudine (N = 369) | Tenofovir Alafenamide– Based Regimen (N = 372) |
|---|---|---|
| Age, y | ||
| Median (range) | 40 (20–74) | 39 (18–73) |
| Age ≥50, n (%) | 79 (21.4) | 92 (24.7) |
| Sex, n (%) | ||
| Female | 25 (6.8) | 33 (8.9) |
| Male | 344 (93.2) | 339 (91.1) |
| Race, n (%) | ||
| African American/African heritage | 50 (13.6) | 58 (15.6) |
| Asian | 13 (3.5) | 13 (3.5) |
| White | 297 (80.5) | 289 (77.7) |
| Other | 9 (2.4) | 12 (3.2) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 69 (18.7) | 66 (17.7) |
| Not Hispanic or Latino | 300 (81.3) | 306 (82.3) |
| Median CD4+ cell count, cells/mm3 (range) | 682 (133–1904) | 720 (119–1810) |
| CD4+ cell count, cells/mm3, n (%) | ||
| <500 | 98 (26.6) | 74 (19.9) |
| ≥500 | 271 (73.4) | 298 (80.1) |
| Baseline third agent class | ||
| Integrase strand transfer inhibitor | 289 (78.3) | 296 (79.6) |
| Elvitegravir/cobicistat | 243 (65.9) | 249 (66.9) |
| Nonnucleoside reverse transcriptase inhibitor | 51 (13.8) | 48 (12.9) |
| Rilpivirine | 43 (11.7) | 45 (12.1) |
| Protease inhibitor | 29 (7.9) | 28 (7.5) |
| Boosted darunavir | 25 (6.8) | 27 (7.3) |
| Duration of antiretroviral therapy before day 1, median (range), months | 33.8 (7.1–201.2) | 35.1 (7.0–160.8) |
| Duration of tenofovir alafenamide–based regimen before day 1, median (range), months | 17.7 (3.6–73.7) | 18.2 (3.9–71.2) |